Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.

Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.

The baseline value of neutrophil to lymphocyte ratio (NLR) has been found to be prognostic in patients with metastatic castration resistant prostate cancer (CRPC). We evaluated the impact of baseline NLR and its change in patients receiving enzalutamide. We included consecutive metastatic CRPC patie...

Full description

Bibliographic Details
Main Authors: Vincenza Conteduca, Simon J Crabb, Robert J Jones, Orazio Caffo, Tony Elliott, Emanuela Scarpi, Paolo Fabbri, Lisa Derosa, Francesco Massari, Gianmauro Numico, Sunnya Zarif, Catherine Hanna, Francesca Maines, Helen Joyce, Cristian Lolli, Ugo De Giorgi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4951050?pdf=render

Internet

http://europepmc.org/articles/PMC4951050?pdf=render

Similar Items